Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

NCT04226066 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumors

Interventions

BIOLOGICAL: T601
COMBINATION_PRODUCT: T601+5-FC

Sponsor

Tasly Tianjin Biopharmaceutical Co., Ltd.